| Field | Row 1 | Row 2 |
|---|---|---|
| adsh | 0001437749-25-017106 | 0001437749-25-011052 |
| cik | 744825 | 744825 |
| name | AMERICAN SHARED HOSPITAL SERVICES | AMERICAN SHARED HOSPITAL SERVICES |
| sic | 8071 | 8071 |
| countryba | US | US |
| stprba | CA | CA |
| cityba | SAN FRANCISCO | SAN FRANCISCO |
| zipba | 94111 | 94111 |
| bas1 | 601 MONTGOMERY STREET | 601 MONTGOMERY STREET |
| bas2 | SUITE 1112 | SUITE 1112 |
| baph | 415-788-5300 | 415-788-5300 |
| countryma | US | US |
| stprma | CA | CA |
| cityma | SAN FRANCISCO | SAN FRANCISCO |
| zipma | 94111 | 94111 |
| mas1 | 601 MONTGOMERY STREET | 601 MONTGOMERY STREET |
| mas2 | SUITE 1112 | SUITE 1112 |
| countryinc | US | US |
| stprinc | CA | CA |
| ein | 942918118 | 942918118 |
| former | ||
| changed | ||
| afs | 4-NON | 4-NON |
| wksi | 0 | 0 |
| fye | 1231 | 1231 |
| form | 10-Q | 10-K |
| period | 20250331 | 20241231 |
| fy | 2025 | 2024 |
| fp | Q1 | FY |
| filed | 20250515 | 20250404 |
| accepted | 2025-05-15 12:38:00.0 | 2025-04-04 17:20:00.0 |
| prevrpt | 0 | 0 |
| detail | 1 | 1 |
| instance | asha20250331_10q_htm.xml | asha20241231_10k_htm.xml |
| nciks | 1 | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001437749-25-011052 | 20231231 | Accounts Payable Current | 315000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Accounts Receivable Net Current | 4343000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Accrued Liabilities Current | 1961000.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Related Party; | ||
| 0001437749-25-011052 | 20231231 | Additional Paid In Capital Common Stock | 8232000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Asset Retirement Obligation Related Party Current | 1200000.0000 | USD | 0 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20231231 | Assets | 48162000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Assets Current | 26258000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Common Stock Shares Outstanding | 6300000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20241231 | Gain Loss On Sale Of Property Plant Equipment | 155000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Income Tax Expense Benefit | -623000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20231231 | Increase Decrease In Due To Related Parties | -491000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Intangible Assets Net Excluding Goodwill | 78000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Interest And Other Income Loss | 248000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20231231 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20241231 | Net Cash Provided By Used In Financing Activities | 4405000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Net Income Loss | 92000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Net Income Loss | 518000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20241231 | Net Income Loss | 5566000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Business Combination | 1900000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20231231 | Operating Income Loss | 270000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20240731 | Operating Lease Right Of Use Asset | 149000.0000 | USD | 0 | us-gaap/2024 | Lease Contractual Term= Radiation Therapy Facility In Puebla Mexico; | ||
| 0001437749-25-011052 | 20231231 | Other Accrued Liabilities Current | 1226000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Other Receivables Net Current | 504000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Repayments Of Long Term Debt | 2129000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Restricted Cash And Cash Equivalents At Carrying Value | 118000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Revenue From Contract With Customer Excluding Assessed Tax | 155000.0000 | USD | 4 | us-gaap/2024 | Product Or Service= Equipment Sales; | ||
| 0001437749-25-011052 | 20231231 | Share Based Compensation | 389000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 8605000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20231231 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 4 | us-gaap/2024 | Award Type= Restricted Stock; | ||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Share Based Compensation | 373000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20231231 | Weighted Average Number Of Diluted Shares Outstanding | 6393000.0000 | shares | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Weighted Average Number Of Shares Outstanding Basic | 6358000.0000 | shares | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Accounts Payable Current | 1562000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Business Combination Bargain Purchase Gain Recognized Amount | 0.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -2533000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Common Stock Shares Issued | 6300000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Depreciation And Amortization | 1639000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Earnings Per Share Diluted | 0.1000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Goodwill | 1265000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Increase Decrease In Accounts Payable And Accrued Liabilities | -79000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Increase Decrease In Accrued Income Taxes Payable | -1229000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Land | 19000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Land | 19000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Liabilities And Stockholders Equity | 48162000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Liabilities Current | 10405000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Noncash Lease Expense | -34000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Business Combination | 1900000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20231231 | Operating Lease Liability Noncurrent | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241130 | Operating Lease Right Of Use Asset | 15000.0000 | USD | 0 | us-gaap/2024 | Lease Contractual Term= Small Office Sublease In San Francisco; | ||
| 0001437749-25-011052 | 20240430 | Payments To Acquire Property Plant And Equipment | 175000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Southern New England Regional Cancer Center L L C And Roger Williams Radiation Therapy L L C; Property Plant And Equipment By Type= Ge Discovery Rt Ct Simulator; | ||
| 0001437749-25-011052 | 20241231 | Payments To Acquire Property Plant And Equipment | 7938000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Proceeds From Lines Of Credit | 10900000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Profit Loss | -345000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20241231 | Profit Loss | 2186000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20241231 | Repayments Of Long Term Debt | 2734000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Repayments Of Long Term Lines Of Credit | 13400000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20221231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 7843000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20221231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 10763000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 10763000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 10763000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20231231 | Write Down Of Impaired Assets And Associated Removal Costs | 940000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Additional Paid In Capital Common Stock | 8605000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Allowance For Doubtful Accounts Receivable Current | 100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Assets Current | 20456000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Business Combination Bargain Purchase Gain Recognized Amount | 3794000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 13808000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Deferred Income Taxes And Tax Credits | 1220000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Deferred Income Tax Liabilities Net | 63000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Depreciation And Amortization | 5165000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Earnings Per Share Basic | 0.1000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Gross Profit | 9185000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Income Tax Expense Benefit | -295000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Increase Decrease In Accounts Payable And Accrued Liabilities | 2227000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Increase Decrease In Asset Retirement Obligations Related Party | -588000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20231231 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -21000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 513000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Interest Expense | 132000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20241231 | Liabilities | 30170000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Net Cash Provided By Used In Operating Activities | 5718000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Net Income Loss Attributable To Noncontrolling Interest | -654000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Business Combination | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20241231 | Other Accrued Liabilities Current | 1888000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Other Receivables Net Current | 503000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Payments To Minority Shareholders | 95000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Prepaid Expense And Other Assets Current | 928000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Proceeds From Issuance Of Long Term Debt | 9860000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Profit Loss | 610000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20241231 | Profit Loss | 2186000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20231231 | Revenue From Contract With Customer Excluding Assessed Tax | 3553000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Revenue From Contract With Customer Excluding Assessed Tax | 17772000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20241231 | Revenue From Contract With Customer Excluding Assessed Tax | 28340000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 8232000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 3655000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 22624000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20231231 | Stock Issued During Period Value Share Based Compensation | 389000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Stock Issued During Period Value Share Based Compensation | 389000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Share Based Compensation | 373000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20241231 | Weighted Average Number Of Shares Outstanding Basic | 6497000.0000 | shares | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Write Down Of Impaired Assets And Associated Removal Costs | 3084000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Write Down Of Impaired Assets And Associated Removal Costs | 3084000.0000 | USD | 4 | 0001437749-25-011052 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20250331 | Allowance For Doubtful Accounts Receivable Current | 280000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Assets | 35455000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20250331 | Assets Current | 23742000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 13042000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 11491000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2025 | ||||
| 0001437749-25-017106 | 20241231 | Common Stock Shares Outstanding | 6420000.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20250331 | Common Stock Value | 10763000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Gross Profit | 2143000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -1235000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Income Taxes Paid Net | 17000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Income Taxes Paid Net | 129000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Increase Decrease In Accounts Receivable | 2138000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -412000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Interest And Other Income Loss | 106000.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20250331 | Long Term Debt Noncurrent | 16798000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Net Cash Provided By Used In Investing Activities | -1183000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Net Income Loss | -82000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20240331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20250331 | Operating Lease Liability Noncurrent | 3667000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240731 | Operating Lease Right Of Use Asset | 149000.0000 | USD | 0 | us-gaap/2025 | Lease Contractual Term= Radiation Therapy Facility In Puebla Mexico; | ||
| 0001437749-25-017106 | 20241231 | Prepaid Expense And Other Assets Current | 928000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Profit Loss | 65000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Profit Loss | 119000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20250331 | Stockholders Equity | 24647000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 3544000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 30000.0000 | shares | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Award Type= Restricted Stock; Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Award Type= Restricted Stock; Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Share Based Compensation | 98000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 6576000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Additional Paid In Capital Common Stock | 8694000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Asset Retirement Obligation Related Party Current | 1200000.0000 | USD | 0 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20241231 | Assets | 24742000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20250331 | Capital Expenditures Incurred But Not Yet Paid | 2160000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Cash And Cash Equivalents At Carrying Value | 11025000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Common Stock No Par Value | 0.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Common Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Common Stock Shares Outstanding | 6330000.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20250331 | Common Stock Shares Outstanding | 6450000.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Cost Depreciation Amortization And Depletion | 1297000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Deferred Income Tax Liabilities Net | 924000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Depreciation And Amortization | 242000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20250331 | Earnings Per Share Basic | -0.1000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Earnings Per Share Diluted | 0.0200 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250630 | Earnings Per Share Diluted | 0.0000 | USD | 1 | us-gaap/2025 | Change In Accounting Estimate By Type= Salvage Value; Property Plant And Equipment By Type= Gamma Knife Units; Scenario= Scenario Forecast; | ||
| 0001437749-25-017106 | 20250331 | Employee Related Liabilities Current | 861000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Gross Profit | 942000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Intangible Assets Net Excluding Goodwill | 78000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Interest Expense | 349000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Interest Paid Net | 409000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Liabilities And Stockholders Equity | 60197000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Lines Of Credit Current | 2000000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 95000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20240331 | Net Income Loss | 119000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Net Income Loss Attributable To Noncontrolling Interest | -54000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Net Income Loss Attributable To Noncontrolling Interest | -287000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Operating Lease Right Of Use Asset | 2071000.0000 | USD | 0 | us-gaap/2025 | Business Acquisition= Ri Companies; Lease Contractual Term= Facility In Warwick Ri; | ||
| 0001437749-25-017106 | 20250228 | Operating Lease Right Of Use Asset | 26000.0000 | USD | 0 | us-gaap/2025 | Lease Contractual Term= Small Office Sublease In Downers Grove; | ||
| 0001437749-25-017106 | 20241231 | Other Receivables Net Current | 503000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240430 | Payments To Acquire Property Plant And Equipment | 175000.0000 | USD | 0 | us-gaap/2025 | Business Acquisition= Southern New England Regional Cancer Center L L C And Roger Williams Radiation Therapy L L C; Property Plant And Equipment By Type= Ge Discovery Rt Ct Simulator; | ||
| 0001437749-25-017106 | 20250331 | Proceeds From Minority Shareholders | 8000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Profit Loss | -287000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 3121000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 3121000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Patient Income; | ||
| 0001437749-25-017106 | 20240331 | Selling General And Administrative Expense | 1879000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Selling General And Administrative Expense | 1808000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 8232000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 10763000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 26385000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 10763000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 3748000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Share Based Compensation | 89000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Share Based Compensation | 89000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20241231 | Accrued Income Taxes | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Asset Retirement Obligation Incurred Through Noncash | 1138000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20221231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 12453000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 1355000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Write Down Of Impaired Assets And Associated Removal Costs | 0.0000 | USD | 4 | 0001437749-25-011052 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Common Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Common Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Common Stock Shares Outstanding | 6300000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Common Stock Shares Outstanding | 6420000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20241231 | Cost Of Revenue | 19155000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Depreciation And Amortization | 736000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20241231 | Direct Operating Maintenance Supplies Costs | 2343000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Goodwill | 1265000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Income Taxes Paid Net | 1846000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Income Tax Expense Benefit | 125000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Increase Decrease In Accrued Income Taxes Payable | 974000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Interest And Other Income Loss | 426000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Interest Expense | 1499000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Interest Paid Net | 1404000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Long Term Debt Current | 2084000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Long Term Debt Noncurrent | 17341000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Minority Interest | 3655000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Minority Interest | 4844000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20241231 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20241231 | Net Income Loss | -3380000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 38000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20241231 | Operating Income Loss | -2805000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Payments To Minority Shareholders | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Prepaid Maintenance Current | 1275000.0000 | USD | 0 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Prepaid Maintenance Current | 1392000.0000 | USD | 0 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20231231 | Repayments Of Long Term Lines Of Credit | 1400000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Repayments Of Short Term Debt | 202000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Restricted Cash | 118000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Restricted Cash And Cash Equivalents At Carrying Value | 250000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Retained Earnings Accumulated Deficit | 5815000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Share Based Compensation | 373000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 26279000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20231231 | Stock Issued During Period Value Share Based Compensation | 389000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Share Based Compensation | 373000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Accrued Liabilities Current | 1320000.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Related Party; | ||
| 0001437749-25-011052 | 20231231 | Asset Retirement Obligation Related Party Current | 650000.0000 | USD | 0 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Business Combination Bargain Purchase Gain Recognized Amount | 3794000.0000 | USD | 3 | us-gaap/2024 | Business Acquisition= Southern New England Regional Cancer Center L L C And Roger Williams Radiation Therapy L L C; | ||
| 0001437749-25-011052 | 20241231 | Cost Depreciation Amortization And Depletion | 6069000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Cost Of Revenue | 11981000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Deferred Income Tax Expense Benefit | -359000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Depreciation And Amortization | 4535000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20231231 | Employee Related Liabilities Current | 757000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Employee Related Liabilities Current | 1368000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Income Tax Expense Benefit | 306000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20231231 | Interest Expense | 25000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20241231 | Liabilities And Stockholders Equity | 60197000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Long Term Debt Noncurrent | 11041000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 95000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Net Cash Provided By Used In Operating Activities | 167000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Business Combination | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20231231 | Other Assets Noncurrent | 443000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Payments Of Debt Issuance Costs | 9000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Proceeds From Lines Of Credit | 3900000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Profit Loss | 265000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Profit Loss | -654000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20241231 | Selling General And Administrative Expense | 7407000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Stockholders Equity | 25183000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20221231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 21625000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20231231 | Unfavorable Lease Position | 0.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Weighted Average Number Of Diluted Shares Outstanding | 6703000.0000 | shares | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Write Down Of Impaired Assets And Associated Removal Costs | 0.0000 | USD | 4 | 0001437749-25-011052 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Asset Retirement Obligation Current | 250000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Accrued Income Taxes | 1229000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Allowance For Doubtful Accounts Receivable Current | 265000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Assets | 39854000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20241231 | Assets | 60197000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Assets | 35455000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20240430 | Business Combination Bargain Purchase Gain Recognized Amount | 3679000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Southern New England Regional Cancer Center L L C And Roger Williams Radiation Therapy L L C; | ||
| 0001437749-25-011052 | 20241231 | Business Combination Bargain Purchase Gain Recognized Amount | 3794000.0000 | USD | 4 | us-gaap/2024 | Business Acquisition= Southern New England Regional Cancer Center L L C And Roger Williams Radiation Therapy L L C; | ||
| 0001437749-25-011052 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 11275000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Cost Depreciation Amortization And Depletion | 5073000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Depreciation And Amortization | 6174000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Gross Profit | 9344000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Income Taxes Paid Net | 297000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Income Taxes Receivable | 550000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Income Tax Expense Benefit | 431000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Income Tax Expense Benefit | 328000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Increase Decrease In Accounts Receivable | 719000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Increase Decrease In Accounts Receivable | 6939000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Increase Decrease In Due To Related Parties | 324000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Increase Decrease In Operating Lease Liability | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Increase Decrease In Operating Lease Liability | -228000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Liabilities | 21883000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Net Cash Provided By Used In Financing Activities | 1910000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Net Cash Provided By Used In Investing Activities | -6273000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 38000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Operating Lease Liability Current | 57000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Other Cost Of Operating Revenue Related Party | 851000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Payments Of Debt Issuance Costs | 164000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Payments To Acquire Property Plant And Equipment | 6273000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Proceeds From Minority Shareholders | 38000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Profit Loss | 610000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20241231 | Profit Loss | 1532000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Revenue From Contract With Customer Excluding Assessed Tax | 12556000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20241231 | Revenue From Contract With Customer Excluding Assessed Tax | 12556000.0000 | USD | 4 | us-gaap/2024 | Product Or Service= Patient Income; | ||
| 0001437749-25-011052 | 20231231 | Selling General And Administrative Expense | 7022000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20221231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 3019000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 3629000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20231231 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 116000.0000 | shares | 4 | us-gaap/2024 | Award Type= Restricted Stock; Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20231231 | Write Down Of Impaired Assets And Associated Removal Costs | 940000.0000 | USD | 4 | 0001437749-25-011052 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20241231 | Allowance For Doubtful Accounts Receivable Current | 265000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Asset Retirement Obligation Related Party Current | 1200000.0000 | USD | 0 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20250331 | Assets | 63311000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Assets Current | 26258000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 216000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20231231 | Common Stock Shares Outstanding | 6300000.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20250331 | Cost Depreciation Amortization And Depletion | 1445000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Cost Of Revenue | 3073000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Increase Decrease In Accounts Payable And Accrued Liabilities | -883000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Increase Decrease In Accrued Income Taxes Payable | -49000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Increase Decrease In Operating Lease Liability | -157000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Interest Expense | 316000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20250331 | Land | 1305000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Minority Interest | 4565000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20240331 | Net Cash Provided By Used In Operating Activities | -1865000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Net Cash Provided By Used In Operating Activities | 2503000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Noncash Lease Expense | 157000.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20240331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20241130 | Operating Lease Right Of Use Asset | 15000.0000 | USD | 0 | us-gaap/2025 | Lease Contractual Term= Small Office Sublease In San Francisco; | ||
| 0001437749-25-017106 | 20240331 | Other Cost Of Operating Revenue Related Party | 170000.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20250331 | Other Cost Of Operating Revenue Related Party | 251000.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20240331 | Payments To Acquire Property Plant And Equipment | 1183000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Payments To Acquire Property Plant And Equipment | 175000.0000 | USD | 3 | us-gaap/2025 | Business Acquisition= Southern New England Regional Cancer Center L L C And Roger Williams Radiation Therapy L L C; Property Plant And Equipment By Type= Ge Discovery Rt Ct Simulator; | ||
| 0001437749-25-017106 | 20250331 | Payments To Acquire Property Plant And Equipment | 4015000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Prepaid Maintenance Current | 930000.0000 | USD | 0 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20250331 | Proceeds From Lines Of Credit | 2000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Property Plant And Equipment Net Excluding Land | 7115000.0000 | USD | 0 | 0001437749-25-017106 | Geographical= Non Us; | ||
| 0001437749-25-017106 | 20240331 | Restricted Cash | 250000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Restricted Cash And Cash Equivalents At Carrying Value | 250000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 4253000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 6112000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 175000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Share Based Compensation | 89000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 8605000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 10763000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Share Based Compensation | 98000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Share Based Compensation | 98000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 6572000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001437749-25-011052 | 20241231 | Asset Retirement Obligation Current | 250000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Assets | 24742000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Capital Expenditures Incurred But Not Yet Paid | 1955000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Capital Expenditures Incurred But Not Yet Paid | 990000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Cash And Cash Equivalents At Carrying Value | 13690000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Deferred Income Tax Expense Benefit | -759000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Gain Loss On Sale Of Property Plant Equipment | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 696000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 1237000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Increase Decrease In Asset Retirement Obligations Related Party | 0.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20231231 | Interest Expense | 1112000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Interest Expense | 1087000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20241231 | Interest Expense | 1367000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20241231 | Lines Of Credit Current | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Long Term Debt Current | 2841000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20241231 | Net Cash Provided By Used In Investing Activities | -7105000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Net Income Loss | 610000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Net Income Loss | 2186000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Business Combination | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20241231 | Operating Lease Liability Current | 226000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Other Cost Of Operating Revenue | 4025000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Other Cost Of Operating Revenue Related Party | 678000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Payments To Acquire Businesses Net Of Cash Acquired | -538000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Payments To Acquire Property Plant And Equipment | 175000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Southern New England Regional Cancer Center L L C And Roger Williams Radiation Therapy L L C; Property Plant And Equipment By Type= Ge Discovery Rt Ct Simulator; | ||
| 0001437749-25-011052 | 20231231 | Proceeds From Sale Of Machinery And Equipment | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Property Plant And Equipment Net Excluding Land | 25844000.0000 | USD | 0 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Property Plant And Equipment Net Excluding Land | 31125000.0000 | USD | 0 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Repayments Of Short Term Debt | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Revenue From Contract With Customer Excluding Assessed Tax | 3353000.0000 | USD | 4 | us-gaap/2024 | Product Or Service= Patient Income; | ||
| 0001437749-25-011052 | 20241231 | Revenue From Contract With Customer Excluding Assessed Tax | 15629000.0000 | USD | 4 | us-gaap/2024 | Product Or Service= Rental Income From Medical Services; | ||
| 0001437749-25-011052 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 4844000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 25183000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 5815000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 120000.0000 | shares | 4 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20241231 | Accounts Payable Current | 1562000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 13808000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Deferred Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Depreciation And Amortization | 550000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20250331 | Direct Operating Maintenance Supplies Costs | 610000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Earnings Per Share Basic | 0.0200 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Employee Related Liabilities Current | 1368000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Goodwill | 1265000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 21000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Income Tax Expense Benefit | -323000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Income Tax Expense Benefit | -257000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20240331 | Interest Expense | 33000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20250331 | Interest Expense | 35000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20241231 | Land | 19000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Liabilities Current | 10405000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20250331 | Net Income Loss | -625000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 38000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Operating Income Loss | -85000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Other Accrued Liabilities Current | 1888000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Other Accrued Liabilities Current | 1843000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Other Cost Of Operating Revenue | 2864000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Other Receivables Net Current | 790000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Prepaid Expense And Other Assets Current | 785000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Prepaid Maintenance Current | 1392000.0000 | USD | 0 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20240331 | Proceeds From Issuance Of Long Term Debt | 2700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Proceeds From Minority Shareholders | 38000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20250331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20250331 | Profit Loss | -625000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20240331 | Repayments Of Long Term Lines Of Credit | 2500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Restricted Cash And Cash Equivalents At Carrying Value | 250000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 26279000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 3629000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Award Type= Restricted Stock; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Share Based Compensation | 89000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20250331 | Accrued Liabilities Current | 2365000.0000 | USD | 0 | us-gaap/2025 | Related Party Transactions By Related Party= Related Party; | ||
| 0001437749-25-017106 | 20241231 | Additional Paid In Capital Common Stock | 8605000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -766000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Common Stock Shares Issued | 6420000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Depreciation And Amortization | 1449000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Income Taxes Receivable | 1009000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Income Tax Expense Benefit | -86000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20250331 | Increase Decrease In Accounts Receivable | -2127000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Increase Decrease In Due To Related Parties | -1898000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Increase Decrease In Due To Related Parties | 59000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -576000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Liabilities And Stockholders Equity | 63311000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Minority Interest | 4844000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20250331 | Net Income Loss | -322000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20240331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20250331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 8000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20240331 | Other Cost Of Operating Revenue | 1093000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Payments Of Debt Issuance Costs | 97000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Proceeds From Lines Of Credit | 2400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Repayments Of Long Term Lines Of Credit | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Retained Earnings Accumulated Deficit | 5190000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 5216000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 963000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 4253000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Rental Income From Medical Services; | ||
| 0001437749-25-017106 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2991000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 22624000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 10763000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 5190000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 30000.0000 | shares | 1 | us-gaap/2025 | Award Type= Restricted Stock; Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Award Type= Restricted Stock; Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20241231 | Long Term Debt Noncurrent | 17341000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Liabilities Current | 12710000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Long Term Debt Current | 3128000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Amortization Of Financing Costs | 38000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Amortization Of Financing Costs | 24000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Asset Retirement Obligation Current | 250000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Assets | 60197000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Assets | 27865000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20240331 | Capital Expenditures Incurred But Not Yet Paid | 1174000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Common Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Common Stock Shares Outstanding | 6420000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Cost Of Revenue | 5170000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Deferred Income Tax Liabilities Net | 924000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Depreciation And Amortization | 1334000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Direct Operating Maintenance Supplies Costs | 513000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Income Taxes Receivable | 550000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Income Tax Expense Benefit | -44000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Income Tax Expense Benefit | -66000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-017106 | 20240331 | Increase Decrease In Accounts Payable And Accrued Liabilities | 268000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Increase Decrease In Accrued Income Taxes Payable | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Increase Decrease In Operating Lease Liability | -21000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Increase To Right Of Use Assets And Lease Liabilities Due To Lease Modification | 2071000.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20250331 | Intangible Assets Net Excluding Goodwill | 78000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Net Income Loss | -303000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20240331 | Noncash Lease Expense | 21000.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20240331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 38000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20250331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20250331 | Operating Income Loss | -1299000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Operating Lease Right Of Use Asset | 1015000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Operating Lease Right Of Use Asset | 3064000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Other Assets Noncurrent | 416000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Payments To Minority Shareholders | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Profit Loss | 119000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20241231 | Property Plant And Equipment Net Excluding Land | 31125000.0000 | USD | 0 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20250331 | Property Plant And Equipment Net Excluding Land | 33441000.0000 | USD | 0 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20240331 | Repayments Of Long Term Debt | 164000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Restricted Cash | 250000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Retained Earnings Accumulated Deficit | 5815000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2991000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Rental Income From Medical Services; | ||
| 0001437749-25-017106 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 8330000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 5815000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 24647000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20240331 | Unfavorable Lease Position | 0.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 6572000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Interest And Other Income Loss | 64000.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20240331 | Income Tax Expense Benefit | 42000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20250331 | Accounts Payable Current | 1231000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Accounts Receivable Net Current | 11610000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Accrued Liabilities Current | 1320000.0000 | USD | 0 | us-gaap/2025 | Related Party Transactions By Related Party= Related Party; | ||
| 0001437749-25-017106 | 20241231 | Asset Retirement Obligation Current | 250000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Assets | 35446000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 11275000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2025 | ||||
| 0001437749-25-017106 | 20250331 | Common Stock Shares Issued | 6450000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Common Stock Shares Outstanding | 6450000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Common Stock Value | 10763000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Deferred Income Tax Expense Benefit | 5000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Earnings Per Share Diluted | -0.1000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Earnings Per Share Diluted | 0.0100 | USD | 1 | us-gaap/2025 | Change In Accounting Estimate By Type= Salvage Value; Property Plant And Equipment By Type= Gamma Knife Units; | ||
| 0001437749-25-017106 | 20250331 | Goodwill | 1265000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Interest Expense | 433000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 95000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Net Cash Provided By Used In Financing Activities | 2282000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Net Cash Provided By Used In Investing Activities | -4015000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Net Income Loss | -83000.0000 | USD | 1 | us-gaap/2025 | Change In Accounting Estimate By Type= Salvage Value; Property Plant And Equipment By Type= Gamma Knife Units; | ||
| 0001437749-25-017106 | 20250331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20241231 | Operating Lease Liability Current | 226000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Operating Lease Liability Noncurrent | 1500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20240331 | Profit Loss | -54000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20250331 | Profit Loss | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001437749-25-017106 | 20241231 | Property Plant And Equipment Net Excluding Land | 6104000.0000 | USD | 0 | 0001437749-25-017106 | Geographical= Non Us; | ||
| 0001437749-25-017106 | 20250331 | Repayments Of Long Term Debt | 280000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 963000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Patient Income; | ||
| 0001437749-25-017106 | 20240331 | Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Stockholders Equity | 25183000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 22841000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 30027000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 4844000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 29212000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 8694000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Award Type= Restricted Stock; Equity Components= Parent; | ||
| 0001437749-25-017106 | 20250331 | Unfavorable Lease Position | 26000.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-011052 | 20231231 | Lines Of Credit Current | 2500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Accounts Receivable Net Current | 11610000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Amortization Of Financing Costs | 46000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Amortization Of Financing Costs | 95000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Asset Retirement Obligation Incurred Through Noncash | 290000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20231231 | Assets | 8308000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Direct Patient Services; | ||
| 0001437749-25-011052 | 20231231 | Business Combination Bargain Purchase Gain Recognized Amount | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Business Combination Bargain Purchase Gain Recognized Amount | 0.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20241231 | Business Combination Bargain Purchase Gain Recognized Amount | 3794000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Business Combination Bargain Purchase Gain Recognized Amount | 0.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20241231 | Cash And Cash Equivalents At Carrying Value | 11025000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001437749-25-011052 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001437749-25-011052 | 20231231 | Common Stock No Par Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Common Stock No Par Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Common Stock Shares Issued | 6420000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20221231 | Common Stock Shares Outstanding | 6184000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20241231 | Common Stock Shares Outstanding | 6420000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Common Stock Value | 10763000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Common Stock Value | 10763000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Deferred Income Tax Liabilities Net | 924000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Depreciation And Amortization | 4429000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20231231 | Direct Operating Maintenance Supplies Costs | 2032000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Earnings Per Share Basic | 0.3400 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Earnings Per Share Diluted | 0.3300 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Income Taxes Receivable | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Intangible Assets Net Excluding Goodwill | 78000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Interest Paid Net | 1066000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Liabilities Current | 10779000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 95000.0000 | USD | 4 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20241231 | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001437749-25-011052 | 20231231 | Net Income Loss Attributable To Noncontrolling Interest | -345000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Noncash Lease Expense | 228000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Business Combination | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Parent; | ||
| 0001437749-25-011052 | 20241231 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-011052 | 20241231 | Operating Lease Liability Noncurrent | 1500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Operating Lease Right Of Use Asset | 57000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Operating Lease Right Of Use Asset | 1015000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Other Assets Noncurrent | 437000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Other Cost Of Operating Revenue | 10065000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Payments To Acquire Businesses Net Of Cash Acquired | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Prepaid Expense And Other Assets Current | 526000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Proceeds From Issuance Of Long Term Debt | 1750000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Proceeds From Minority Shareholders | 0.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Proceeds From Sale Of Machinery And Equipment | 295000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Restricted Cash | 250000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Retained Earnings Accumulated Deficit | 3629000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Revenue From Contract With Customer Excluding Assessed Tax | 21325000.0000 | USD | 4 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20231231 | Revenue From Contract With Customer Excluding Assessed Tax | 200000.0000 | USD | 4 | us-gaap/2024 | Product Or Service= Equipment Sales; | ||
| 0001437749-25-011052 | 20231231 | Revenue From Contract With Customer Excluding Assessed Tax | 17772000.0000 | USD | 4 | us-gaap/2024 | Product Or Service= Rental Income From Medical Services; | ||
| 0001437749-25-011052 | 20241231 | Revenue From Contract With Customer Excluding Assessed Tax | 15784000.0000 | USD | 4 | us-gaap/2024 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-011052 | 20231231 | Stockholders Equity | 22624000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20221231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 25625000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20221231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 4000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 30027000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001437749-25-011052 | 20241231 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 4 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-011052 | 20241231 | Unfavorable Lease Position | 65000.0000 | USD | 4 | 0001437749-25-011052 | |||
| 0001437749-25-011052 | 20231231 | Weighted Average Number Of Shares Outstanding Basic | 123000.0000 | shares | 4 | us-gaap/2024 | Award Type= Restricted Stock Units R S U; | ||
| 0001437749-25-011052 | 20241231 | Weighted Average Number Of Shares Outstanding Basic | 123000.0000 | shares | 4 | us-gaap/2024 | Award Type= Restricted Stock Units R S U; | ||
| 0001437749-25-017106 | 20250331 | Profit Loss | -912000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Profit Loss | -625000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20250331 | Accounts Receivable Net Current | 8737000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Cash And Cash Equivalents At Carrying Value | 12792000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Cash And Cash Equivalents At Carrying Value | 11241000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Common Stock No Par Value | 0.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Depreciation And Amortization | 1092000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20250331 | Depreciation And Amortization | 899000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20240331 | Increase To Right Of Use Assets And Lease Liabilities Due To Lease Modification | 0.0000 | USD | 1 | 0001437749-25-017106 | |||
| 0001437749-25-017106 | 20250331 | Interest Expense | 398000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20240331 | Interest Paid Net | 311000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Liabilities | 30170000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Liabilities | 34099000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Lines Of Credit Current | 0.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Long Term Debt Current | 2841000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Net Cash Provided By Used In Financing Activities | 1728000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Net Income Loss | 201000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Medical Equipment Leasing; | ||
| 0001437749-25-017106 | 20250630 | Net Income Loss | -10000.0000 | USD | 1 | us-gaap/2025 | Change In Accounting Estimate By Type= Salvage Value; Property Plant And Equipment By Type= Gamma Knife Units; Scenario= Scenario Forecast; | ||
| 0001437749-25-017106 | 20250331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 8000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20250331 | Noncontrolling Interest Increase From Subsidiary Equity Issuance | 0.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001437749-25-017106 | 20250331 | Operating Lease Liability Current | 82000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20241231 | Other Assets Noncurrent | 437000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Payments Of Debt Issuance Costs | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Payments To Minority Shareholders | 95000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20250331 | Proceeds From Issuance Of Long Term Debt | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20240331 | Share Based Compensation | 98000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001437749-25-017106 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 3655000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 25183000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Parent; | ||
| 0001437749-25-017106 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 4565000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Noncontrolling Interest; | ||
| 0001437749-25-017106 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 0.0000 | USD | 1 | us-gaap/2025 | Award Type= Restricted Stock; Equity Components= Additional Paid In Capital; | ||
| 0001437749-25-017106 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 6452000.0000 | shares | 1 | us-gaap/2025 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Noncontrolling Interest Increase From Business Combination | us-gaap/2024 | 0 | 0 | monetary | D | C | Noncontrolling Interest, Increase from Business Combination | Amount of increase in noncontrolling interest from a business combination. |
| Proceeds From Issuance Of Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Long-Term Debt | The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. |
| Operating Lease Liability Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Depreciation And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization, Nonproduction | The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash Provided by (Used in) Investing Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets. |
| Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Businesses, Net of Cash Acquired | The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Proceeds From Minority Shareholders | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Noncontrolling Interests | Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership. |
| Proceeds From Sale Of Machinery And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale of Machinery and Equipment | The cash inflow from sale of machinery and equipment. |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | 0 | 0 | monetary | I | D | Cash and Cash Equivalent | Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Common Stock Shares Authorized | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Common Stock No Par Value | us-gaap/2025 | 0 | 0 | perShare | I | Common Stock, No Par Value | Face amount per share of no-par value common stock. | |
| Earnings Per Share Diluted | us-gaap/2025 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Repayments Of Long Term Lines Of Credit | us-gaap/2025 | 0 | 0 | monetary | D | C | Repayments of Long-Term Lines of Credit | The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. |
| Noncash Lease Expense | 0001437749-25-017106 | 1 | 0 | monetary | D | D | ams_NoncashLeaseExpense | The amount of noncash lease expense. |
| Allowance For Doubtful Accounts Receivable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Receivable, Allowance for Credit Loss, Current | Amount of allowance for credit loss on accounts receivable, classified as current. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation | Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Income (Loss) Attributable to Noncontrolling Interest | Amount of Net Income (Loss) attributable to noncontrolling interest. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2025 | 0 | 0 | monetary | I | D | Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation | Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Commitments And Contingencies | us-gaap/2025 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Employee Related Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Employee-related Liabilities, Current | Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Increase Decrease In Operating Lease Liability | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Lines Of Credit Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Line of Credit, Current | The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. |
| Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | us-gaap/2025 | 0 | 0 | monetary | D | D | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders | Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders. |
| Noncontrolling Interest Increase From Subsidiary Equity Issuance | us-gaap/2025 | 0 | 0 | monetary | D | C | Noncontrolling Interest, Increase from Subsidiary Equity Issuance | Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders. |
| Other Accrued Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Other Accrued Liabilities, Current | Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Interest And Other Income Loss | 0001437749-25-011052 | 1 | 0 | monetary | D | C | Interest and other income, net | The amount of interest income (loss) and other income (loss) recognized during the period. |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Unfavorable Lease Position | 0001437749-25-017106 | 1 | 0 | monetary | D | C | ams_UnfavorableLeasePosition | Represents the unfavorable lease position reported as an adjustment to reconcile net income to net cash from operating activities. |
| Asset Retirement Obligation Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Asset Retirement Obligation, Current | Current portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees. |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Payments Of Debt Issuance Costs | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Debt Issuance Costs | The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. |
| Repayments Of Short Term Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Short-Term Debt | The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. |
| Stock Issued During Period Value Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | C | Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture | Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2025 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Selling General And Administrative Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Profit Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Common Stock Shares Issued | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Income Taxes Receivable | us-gaap/2025 | 0 | 0 | monetary | I | D | Income Taxes Receivable, Current | Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. |
| Minority Interest | us-gaap/2025 | 0 | 0 | monetary | I | C | Equity, Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. |
| Stock Issued During Period Value Share Based Compensation | us-gaap/2025 | 0 | 0 | monetary | D | C | Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture | Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). |
| Increase Decrease In Due To Related Parties | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Due to Related Parties | The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence. |
| Asset Retirement Obligation Related Party Current | 0001437749-25-011052 | 1 | 0 | monetary | I | C | Asset retirement obligations, related party (includes $250,000 and $250,000 non-related party at December 31, 2024 and 2023, respectively) | Current portion of the carrying amount of a liability for related party portion of an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees. |
| Deferred Income Tax Liabilities Net | us-gaap/2025 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Direct Operating Maintenance Supplies Costs | us-gaap/2024 | 0 | 0 | monetary | D | D | Direct Operating Maintenance Supplies Costs | Costs of maintenance supplies used that are directly related to goods produced and sold, or services rendered, during the reporting period. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Gross Profit | us-gaap/2024 | 0 | 0 | monetary | D | C | Gross Profit | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Interest Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Operating and Nonoperating | Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. |
| Lines Of Credit Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Line of Credit, Current | The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2025 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Long Term Debt Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Long-Term Debt, Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. |
| Long Term Debt Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Restricted Cash | us-gaap/2025 | 0 | 0 | monetary | I | D | Restricted Cash | Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Prepaid Maintenance Current | 0001437749-25-011052 | 1 | 0 | monetary | I | D | Prepaid maintenance | The amount of prepaid maintenance classified as current. |
| Unfavorable Lease Position | 0001437749-25-011052 | 1 | 0 | monetary | D | C | ams_UnfavorableLeasePosition | Represents the unfavorable lease position reported as an adjustment to reconcile net income to net cash from operating activities. |
| Property Plant And Equipment Net Excluding Land | 0001437749-25-017106 | 1 | 0 | monetary | I | D | Property and equipment, net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale, excluding land. |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cost Depreciation Amortization And Depletion | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost, Depreciation, Amortization and Depletion | Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service. |
| Cost Of Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Revenue | The aggregate cost of goods produced and sold and services rendered during the reporting period. |
| Operating Income Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Increase Decrease In Accrued Income Taxes Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Income Taxes Payable | The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Payments To Minority Shareholders | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Noncontrolling Interests | Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest. |
| Repayments Of Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Long-Term Debt | The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. | |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2025 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Accounts Receivable Net Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Asset Retirement Obligation Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Asset Retirement Obligation, Current | Current portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees. |
| Cost Of Revenue | us-gaap/2025 | 0 | 0 | monetary | D | D | Cost of Revenue | The aggregate cost of goods produced and sold and services rendered during the reporting period. |
| Direct Operating Maintenance Supplies Costs | us-gaap/2025 | 0 | 0 | monetary | D | D | Direct Operating Maintenance Supplies Costs | Costs of maintenance supplies used that are directly related to goods produced and sold, or services rendered, during the reporting period. |
| Increase Decrease In Accrued Income Taxes Payable | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Income Taxes Payable | The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. |
| Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2025 | 0 | 0 | monetary | D | D | Net Income (Loss) Attributable to Noncontrolling Interest | Amount of Net Income (Loss) attributable to noncontrolling interest. |
| Operating Lease Liability Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Operating Lease Right Of Use Asset | us-gaap/2025 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Receivables Net Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Other Receivables, Net, Current | Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. |
| Proceeds From Lines Of Credit | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Lines of Credit | Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Interest And Other Income Loss | 0001437749-25-017106 | 1 | 0 | monetary | D | C | Interest and other income, net | The amount of interest income (loss) and other income (loss) recognized during the period. |
| Other Cost Of Operating Revenue Related Party | 0001437749-25-017106 | 1 | 0 | monetary | D | D | Other direct operating costs, related party | Other costs from related parties incurred during the reporting period related to other revenue generating activities. |
| Business Combination Bargain Purchase Gain Recognized Amount | us-gaap/2024 | 0 | 0 | monetary | D | C | Business Combination, Bargain Purchase, Gain Recognized, Amount | In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity. |
| Income Taxes Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Income Taxes Paid, Net | Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | us-gaap/2024 | 0 | 0 | monetary | D | D | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders | Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Accrued Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Earnings Per Share Basic | us-gaap/2025 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Payments To Acquire Property Plant And Equipment | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Amortization Of Financing Costs | us-gaap/2025 | 0 | 0 | monetary | D | D | Amortization of Debt Issuance Costs | Amount of amortization expense attributable to debt issuance costs. |
| Increase Decrease In Due To Related Parties | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Due to Related Parties | The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2025 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Interest Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Interest Expense, Operating and Nonoperating | Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. |
| Proceeds From Issuance Of Long Term Debt | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Long-Term Debt | The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | us-gaap/2025 | 0 | 0 | monetary | D | D | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Amount of increase in right-of-use asset obtained in exchange for operating lease liability. |
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2025 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. |
| Other Cost Of Operating Revenue Related Party | 0001437749-25-011052 | 1 | 0 | monetary | D | D | Other direct operating costs, related party | Other costs from related parties incurred during the reporting period related to other revenue generating activities. |
| Increase To Right Of Use Assets And Lease Liabilities Due To Lease Modification | 0001437749-25-017106 | 1 | 0 | monetary | D | D | Increase to right of use assets and lease liabilities due to a lease modification | Amount of increase to right of use assets and lease liabilities due to a lease modification. |
| Common Stock No Par Value | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, No Par Value | Face amount per share of no-par value common stock. | |
| Employee Related Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Employee-related Liabilities, Current | Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Deferred Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Income Tax Expense (Benefit) | Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. |
| Land | us-gaap/2024 | 0 | 0 | monetary | I | D | Land | Amount before accumulated depletion of real estate held for productive use, excluding land held for sale. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Restricted Cash | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash | Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash Provided by (Used in) Financing Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit. |
| Common Stock Shares Outstanding | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Deferred Income Tax Expense Benefit | us-gaap/2025 | 0 | 0 | monetary | D | D | Deferred Income Tax Expense (Benefit) | Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. |
| Depreciation And Amortization | us-gaap/2025 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization, Nonproduction | The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. |
| Amortization Of Financing Costs | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Debt Issuance Costs | Amount of amortization expense attributable to debt issuance costs. |
| Other Assets Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Payments Of Debt Issuance Costs | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments of Debt Issuance Costs | The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. |
| Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2025 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. | |
| Asset Retirement Obligation Incurred Through Noncash | 0001437749-25-011052 | 1 | 0 | monetary | D | C | Increase in ARO obligation | Represents the increase in asset retirement obligation through noncash methods. |
| Noncash Lease Expense | 0001437749-25-011052 | 1 | 0 | monetary | D | D | ams_NoncashLeaseExpense | The amount of noncash lease expense. |
| Property Plant And Equipment Net Excluding Land | 0001437749-25-011052 | 1 | 0 | monetary | I | D | PROPERTY AND EQUIPMENT, net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale, excluding land. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Assets | us-gaap/2025 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Increase Decrease In Accounts Receivable | us-gaap/2025 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Liabilities And Stockholders Equity | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Net Income Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Stockholders Equity | us-gaap/2025 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Cost Depreciation Amortization And Depletion | us-gaap/2025 | 0 | 0 | monetary | D | D | Cost, Depreciation, Amortization and Depletion | Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service. |
| Goodwill | us-gaap/2025 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Prepaid Expense And Other Assets Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Repayments Of Long Term Debt | us-gaap/2025 | 0 | 0 | monetary | D | C | Repayments of Long-Term Debt | The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. |
| Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | 0 | 0 | monetary | D | C | Capital Expenditures Incurred but Not yet Paid | Future cash outflow to pay for purchases of fixed assets that have occurred. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Accrued Income Taxes | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Income Taxes | Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes. |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Deferred Income Tax Liabilities Net | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Gain Loss On Sale Of Property Plant Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Disposition of Property Plant Equipment | Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. |
| Income Taxes Receivable | us-gaap/2024 | 0 | 0 | monetary | I | D | Income Taxes Receivable, Current | Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Interest Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Asset Retirement Obligation Related Party Current | 0001437749-25-017106 | 1 | 0 | monetary | I | C | Asset retirement obligations, related party (includes $250,000 and $250,000 non-related party at March 31, 2025 and December 31, 2024) | Current portion of the carrying amount of a liability for related party portion of an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Noncontrolling Interest Increase From Subsidiary Equity Issuance | us-gaap/2024 | 0 | 0 | monetary | D | C | Noncontrolling Interest, Increase from Subsidiary Equity Issuance | Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders. |
| Other Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Accrued Liabilities, Current | Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. |
| Proceeds From Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Lines of Credit | Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. |
| Assets Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Gross Profit | us-gaap/2025 | 0 | 0 | monetary | D | C | Gross Profit | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Income Tax Expense Benefit | us-gaap/2025 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. |
| Liabilities | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Capital Expenditures Incurred But Not Yet Paid | us-gaap/2025 | 0 | 0 | monetary | D | C | Capital Expenditures Incurred but Not yet Paid | Future cash outflow to pay for purchases of fixed assets that have occurred. |
| Interest Paid Net | us-gaap/2025 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activity | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Land | us-gaap/2025 | 0 | 0 | monetary | I | D | Land | Amount before accumulated depletion of real estate held for productive use, excluding land held for sale. |
| Other Cost Of Operating Revenue | us-gaap/2025 | 0 | 0 | monetary | D | D | Other Cost of Operating Revenue | Other costs incurred during the reporting period related to other revenue generating activities. |
| Payments To Minority Shareholders | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Noncontrolling Interests | Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest. |
| Share Based Compensation | us-gaap/2025 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2025 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Increase Decrease In Asset Retirement Obligations Related Party | 0001437749-25-011052 | 1 | 0 | monetary | D | D | ams_IncreaseDecreaseInAssetRetirementObligationsRelatedParty | The amount of increase decrease in asset retirement obligations from related parties. |
| Write Down Of Impaired Assets And Associated Removal Costs | 0001437749-25-011052 | 1 | 0 | monetary | D | D | Loss on write down of impaired assets | Amount of write down of impaired assets and associated removal costs. |
| Prepaid Maintenance Current | 0001437749-25-017106 | 1 | 0 | monetary | I | D | Prepaid maintenance | The amount of prepaid maintenance classified as current. |
| Accounts Payable Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Deferred Income Taxes And Tax Credits | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Income Taxes and Tax Credits | Amount of deferred income tax expense (benefit) and income tax credits. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Cost Of Operating Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Cost of Operating Revenue | Other costs incurred during the reporting period related to other revenue generating activities. |
| Other Receivables Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Receivables, Net, Current | Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. |
| Restricted Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash and Cash Equivalents, Current | Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Additional Paid In Capital Common Stock | us-gaap/2025 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Repayments Of Long Term Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Long-Term Lines of Credit | The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. |
| Long Term Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. |
| Long Term Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Minority Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Net Cash Provided By Used In Operating Activities | us-gaap/2025 | 0 | 0 | monetary | D | Cash Provided by (Used in) Operating Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity. | |
| Retained Earnings Accumulated Deficit | us-gaap/2025 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Common Stock Value | us-gaap/2025 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Income Taxes Paid Net | us-gaap/2025 | 0 | 0 | monetary | D | C | Income Taxes Paid, Net | Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. |
| Allowance For Doubtful Accounts Receivable Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Accounts Receivable, Allowance for Credit Loss, Current | Amount of allowance for credit loss on accounts receivable, classified as current. |
| Proceeds From Minority Shareholders | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Noncontrolling Interests | Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership. |
| Restricted Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | 0 | 0 | monetary | I | D | Restricted Cash and Cash Equivalent, Current | Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001437749-25-017106 | 2 | 9 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | Cash and cash equivalents | 0 |
| 0001437749-25-011052 | 2 | 9 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001437749-25-011052 | 2 | 10 | BS | 0 | H | Restricted Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Restricted cash | 0 |
| 0001437749-25-011052 | 2 | 11 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable, net of allowance for credit losses of $265,000 and $100,000 at December 31, 2024 and December 31, 2023, respectively | 0 |
| 0001437749-25-011052 | 2 | 12 | BS | 0 | H | Income Taxes Receivable | us-gaap/2024 | Tax receivables | 0 |
| 0001437749-25-011052 | 2 | 13 | BS | 0 | H | Other Receivables Net Current | us-gaap/2024 | Other receivables | 0 |
| 0001437749-25-011052 | 2 | 14 | BS | 0 | H | Prepaid Maintenance Current | 0001437749-25-011052 | Prepaid maintenance | 0 |
| 0001437749-25-011052 | 2 | 15 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001437749-25-011052 | 2 | 16 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001437749-25-011052 | 2 | 17 | BS | 0 | H | Property Plant And Equipment Net Excluding Land | 0001437749-25-011052 | PROPERTY AND EQUIPMENT, net | 0 |
| 0001437749-25-011052 | 2 | 18 | BS | 0 | H | Land | us-gaap/2024 | LAND | 0 |
| 0001437749-25-011052 | 2 | 19 | BS | 0 | H | Goodwill | us-gaap/2024 | GOODWILL | 0 |
| 0001437749-25-011052 | 2 | 20 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | INTANGIBLE ASSETS | 0 |
| 0001437749-25-011052 | 2 | 21 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | RIGHT OF USE ASSETS, net | 0 |
| 0001437749-25-011052 | 2 | 22 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | OTHER ASSETS | 0 |
| 0001437749-25-011052 | 2 | 23 | BS | 0 | H | Assets | us-gaap/2024 | TOTAL ASSETS | 0 |
| 0001437749-25-011052 | 2 | 25 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001437749-25-011052 | 2 | 26 | BS | 0 | H | Employee Related Liabilities Current | us-gaap/2024 | Employee compensation and benefits | 0 |
| 0001437749-25-011052 | 2 | 27 | BS | 0 | H | Other Accrued Liabilities Current | us-gaap/2024 | Other accrued liabilities | 0 |
| 0001437749-25-011052 | 2 | 28 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Related party liabilities | 0 |
| 0001437749-25-011052 | 2 | 29 | BS | 0 | H | Asset Retirement Obligation Related Party Current | 0001437749-25-011052 | Asset retirement obligations, related party (includes $250,000 and $250,000 non-related party at December 31, 2024 and 2023, respectively) | 0 |
| 0001437749-25-011052 | 2 | 30 | BS | 0 | H | Accrued Income Taxes | us-gaap/2024 | Income taxes payable | 0 |
| 0001437749-25-011052 | 2 | 31 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Current portion of lease liabilities | 0 |
| 0001437749-25-011052 | 2 | 32 | BS | 0 | H | Lines Of Credit Current | us-gaap/2024 | Line of credit | 0 |
| 0001437749-25-011052 | 2 | 33 | BS | 0 | H | Long Term Debt Current | us-gaap/2024 | Current portion of long-term debt, net | 0 |
| 0001437749-25-011052 | 2 | 34 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001437749-25-011052 | 2 | 35 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | LONG-TERM LEASE LIABILITIES, less current portion | 0 |
| 0001437749-25-011052 | 2 | 36 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2024 | LONG-TERM DEBT, net, less current portion | 0 |
| 0001437749-25-011052 | 2 | 37 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2024 | DEFERRED INCOME TAXES | 0 |
| 0001437749-25-011052 | 2 | 38 | BS | 0 | H | Liabilities | us-gaap/2024 | TOTAL LIABILITIES | 0 |
| 0001437749-25-011052 | 2 | 39 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | COMMITMENTS AND CONTINGENCIES (See Note 10) | 0 |
| 0001437749-25-011052 | 2 | 41 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, no par value (10,000,000 authorized shares; Issued and outstanding shares 6,420,000 at December 31, 2024 and 6,300,000 at December 31, 2023) | 0 |
| 0001437749-25-011052 | 2 | 42 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001437749-25-011052 | 2 | 43 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Retained earnings | 0 |
| 0001437749-25-011052 | 2 | 44 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total equity- American Shared Hospital Services | 0 |
| 0001437749-25-011052 | 2 | 45 | BS | 0 | H | Minority Interest | us-gaap/2024 | Non-controlling interests in subsidiaries | 0 |
| 0001437749-25-011052 | 2 | 46 | BS | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Total shareholders equity | 0 |
| 0001437749-25-011052 | 2 | 47 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 0 |
| 0001437749-25-011052 | 3 | 5 | BS | 1 | H | Allowance For Doubtful Accounts Receivable Current | us-gaap/2024 | Allowance for doubtful accounts | 0 |
| 0001437749-25-011052 | 3 | 6 | BS | 1 | H | Asset Retirement Obligation Current | us-gaap/2024 | Asser retirement obligations, non-related party | 0 |
| 0001437749-25-011052 | 3 | 7 | BS | 1 | H | Common Stock No Par Value | us-gaap/2024 | Common stock, no par value (in dollars per share) | 0 |
| 0001437749-25-011052 | 3 | 8 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized (in shares) | 0 |
| 0001437749-25-011052 | 3 | 9 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued (in shares) | 0 |
| 0001437749-25-011052 | 3 | 10 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding (in shares) | 0 |
| 0001437749-25-011052 | 4 | 10 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Revenues | 0 |
| 0001437749-25-011052 | 4 | 12 | IS | 0 | H | Direct Operating Maintenance Supplies Costs | us-gaap/2024 | Maintenance and supplies | 0 |
| 0001437749-25-011052 | 4 | 13 | IS | 0 | H | Cost Depreciation Amortization And Depletion | us-gaap/2024 | Depreciation and amortization | 0 |
| 0001437749-25-011052 | 4 | 14 | IS | 0 | H | Other Cost Of Operating Revenue | us-gaap/2024 | Other direct operating costs | 0 |
| 0001437749-25-011052 | 4 | 15 | IS | 0 | H | Other Cost Of Operating Revenue Related Party | 0001437749-25-011052 | Other direct operating costs, related party | 0 |
| 0001437749-25-011052 | 4 | 16 | IS | 0 | H | Cost Of Revenue | us-gaap/2024 | Cost of Revenue | 0 |
| 0001437749-25-011052 | 4 | 17 | IS | 0 | H | Gross Profit | us-gaap/2024 | Gross margin | 0 |
| 0001437749-25-011052 | 4 | 18 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling and administrative expense | 0 |
| 0001437749-25-011052 | 4 | 19 | IS | 0 | H | Interest Expense | us-gaap/2024 | Interest expense | 0 |
| 0001437749-25-011052 | 4 | 20 | IS | 0 | H | Write Down Of Impaired Assets And Associated Removal Costs | 0001437749-25-011052 | Loss on write down of impaired assets | 0 |
| 0001437749-25-011052 | 4 | 21 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Operating (loss) income | 0 |
| 0001437749-25-011052 | 4 | 22 | IS | 0 | H | Business Combination Bargain Purchase Gain Recognized Amount | us-gaap/2024 | Bargain purchase gain RI Acquisition, net of deferred income taxes of $1,220,000 | 0 |
| 0001437749-25-011052 | 4 | 23 | IS | 0 | H | Interest And Other Income Loss | 0001437749-25-011052 | Interest and other income, net | 0 |
| 0001437749-25-011052 | 4 | 24 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Income before income taxes | 0 |
| 0001437749-25-011052 | 4 | 25 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax (benefit) expense | 0 |
| 0001437749-25-011052 | 4 | 26 | IS | 0 | H | Profit Loss | us-gaap/2024 | Net income | 0 |
| 0001437749-25-011052 | 4 | 27 | IS | 0 | H | Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | (Plus): net loss attributable to non-controlling interests | 1 |
| 0001437749-25-011052 | 4 | 28 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net income attributable to American Shared Hospital Services | 0 |
| 0001437749-25-011052 | 4 | 30 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Earnings per common share - basic (in dollars per share) | 0 |
| 0001437749-25-011052 | 4 | 31 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Earnings per common share - diluted (in dollars per share) | 0 |
| 0001437749-25-011052 | 4 | 32 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted average common shares for basic earnings per share (in shares) | 0 |
| 0001437749-25-011052 | 4 | 33 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted average common shares for diluted earnings per share (in shares) | 0 |
| 0001437749-25-011052 | 5 | 5 | IS | 1 | H | Deferred Income Taxes And Tax Credits | us-gaap/2024 | Deferred income taxes | 0 |
| 0001437749-25-011052 | 6 | 13 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Balances (in shares) | 0 |
| 0001437749-25-011052 | 6 | 14 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Balances | 0 |
| 0001437749-25-011052 | 6 | 15 | EQ | 0 | H | Stock Issued During Period Value Share Based Compensation | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001437749-25-011052 | 6 | 16 | EQ | 0 | H | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | Vested restricted stock awards (in shares) | 0 |
| 0001437749-25-011052 | 6 | 17 | EQ | 0 | H | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | Vested restricted stock awards | 0 |
| 0001437749-25-011052 | 6 | 18 | EQ | 0 | H | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | us-gaap/2024 | Cash distributions to non-controlling interests | 1 |
| 0001437749-25-011052 | 6 | 19 | EQ | 0 | H | Profit Loss | us-gaap/2024 | Net income | 0 |
| 0001437749-25-011052 | 6 | 20 | EQ | 0 | H | Noncontrolling Interest Increase From Subsidiary Equity Issuance | us-gaap/2024 | Capital contributions from non-controlling interests | 0 |
| 0001437749-25-011052 | 6 | 21 | EQ | 0 | H | Noncontrolling Interest Increase From Business Combination | us-gaap/2024 | RI Acquisition non-controlling interests | 0 |
| 0001437749-25-011052 | 6 | 22 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Balances (in shares) | 0 |
| 0001437749-25-011052 | 6 | 23 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Balances | 0 |
| 0001437749-25-011052 | 7 | 6 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net income | 0 |
| 0001437749-25-011052 | 7 | 8 | CF | 0 | H | Depreciation And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0001437749-25-011052 | 7 | 9 | CF | 0 | H | Noncash Lease Expense | 0001437749-25-011052 | Non cash lease expense | 0 |
| 0001437749-25-011052 | 7 | 10 | CF | 0 | H | Amortization Of Financing Costs | us-gaap/2024 | Accretion of deferred issuance costs | 0 |
| 0001437749-25-011052 | 7 | 11 | CF | 0 | H | Write Down Of Impaired Assets And Associated Removal Costs | 0001437749-25-011052 | Loss on write down of impaired assets | 0 |
| 0001437749-25-011052 | 7 | 12 | CF | 0 | H | Gain Loss On Sale Of Property Plant Equipment | us-gaap/2024 | Gain on sale of equipment | 1 |
| 0001437749-25-011052 | 7 | 13 | CF | 0 | H | Business Combination Bargain Purchase Gain Recognized Amount | us-gaap/2024 | Bargain purchase gain RI Acquisition, net of deferred income taxes | 1 |
| 0001437749-25-011052 | 7 | 14 | CF | 0 | H | Deferred Income Tax Expense Benefit | us-gaap/2024 | Deferred income taxes | 0 |
| 0001437749-25-011052 | 7 | 15 | CF | 0 | H | Unfavorable Lease Position | 0001437749-25-011052 | Accretion of unfavorable lease position | 1 |
| 0001437749-25-011052 | 7 | 16 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0001437749-25-011052 | 7 | 18 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Receivables | 1 |
| 0001437749-25-011052 | 7 | 19 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other assets | 1 |
| 0001437749-25-011052 | 7 | 20 | CF | 0 | H | Increase Decrease In Asset Retirement Obligations Related Party | 0001437749-25-011052 | Asset retirement obligations, related party | 0 |
| 0001437749-25-011052 | 7 | 21 | CF | 0 | H | Increase Decrease In Due To Related Parties | us-gaap/2024 | Related party liabilities | 0 |
| 0001437749-25-011052 | 7 | 22 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Lease liability | 0 |
| 0001437749-25-011052 | 7 | 23 | CF | 0 | H | Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | Accounts payable and accrued liabilities | 0 |
| 0001437749-25-011052 | 7 | 24 | CF | 0 | H | Increase Decrease In Accrued Income Taxes Payable | us-gaap/2024 | Income taxes payable | 0 |
| 0001437749-25-011052 | 7 | 25 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash provided by operating activities | 0 |
| 0001437749-25-011052 | 7 | 27 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Payment for purchases of property and equipment | 1 |
| 0001437749-25-011052 | 7 | 28 | CF | 0 | H | Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | Cash received in excess of cash paid for RI Acquisition | 1 |
| 0001437749-25-011052 | 7 | 29 | CF | 0 | H | Proceeds From Sale Of Machinery And Equipment | us-gaap/2024 | Proceeds from sale of equipment | 0 |
| 0001437749-25-011052 | 7 | 30 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash (used in) investing activities | 0 |
| 0001437749-25-011052 | 7 | 32 | CF | 0 | H | Repayments Of Long Term Debt | us-gaap/2024 | Principal payments on long-term debt | 1 |
| 0001437749-25-011052 | 7 | 33 | CF | 0 | H | Repayments Of Long Term Lines Of Credit | us-gaap/2024 | Principal payments on line of credit | 1 |
| 0001437749-25-011052 | 7 | 34 | CF | 0 | H | Proceeds From Lines Of Credit | us-gaap/2024 | Advances on line of credit | 0 |
| 0001437749-25-011052 | 7 | 35 | CF | 0 | H | Proceeds From Issuance Of Long Term Debt | us-gaap/2024 | Long-term debt financing on purchase of property and equipment | 0 |
| 0001437749-25-011052 | 7 | 36 | CF | 0 | H | Payments Of Debt Issuance Costs | us-gaap/2024 | Debt issuance costs long-term debt | 1 |
| 0001437749-25-011052 | 7 | 37 | CF | 0 | H | Payments To Minority Shareholders | us-gaap/2024 | Distributions to non-controlling interests | 1 |
| 0001437749-25-011052 | 7 | 38 | CF | 0 | H | Proceeds From Minority Shareholders | us-gaap/2024 | Capital contributions from non-controlling interests | 0 |
| 0001437749-25-011052 | 7 | 39 | CF | 0 | H | Repayments Of Short Term Debt | us-gaap/2024 | Principal payments on short-term financing prepaid insurance | 1 |
| 0001437749-25-011052 | 7 | 40 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0001437749-25-011052 | 7 | 41 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net change in cash and cash equivalents | 0 |
| 0001437749-25-011052 | 7 | 42 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year | 0 |
| 0001437749-25-011052 | 7 | 43 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year | 0 |
| 0001437749-25-011052 | 7 | 45 | CF | 0 | H | Interest Paid Net | us-gaap/2024 | Cash paid for interest | 0 |
| 0001437749-25-011052 | 7 | 46 | CF | 0 | H | Income Taxes Paid Net | us-gaap/2024 | Cash paid for income taxes | 0 |
| 0001437749-25-011052 | 7 | 48 | CF | 0 | H | Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | Equipment included in accounts payable and accrued liabilities | 0 |
| 0001437749-25-011052 | 7 | 49 | CF | 0 | H | Asset Retirement Obligation Incurred Through Noncash | 0001437749-25-011052 | Increase in ARO obligation | 0 |
| 0001437749-25-011052 | 7 | 51 | CF | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001437749-25-011052 | 7 | 52 | CF | 0 | H | Restricted Cash | us-gaap/2024 | Restricted cash | 0 |
| 0001437749-25-011052 | 7 | 53 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year | 0 |
| 0001437749-25-017106 | 2 | 10 | BS | 0 | H | Restricted Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | Restricted cash | 0 |
| 0001437749-25-017106 | 2 | 11 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2025 | Accounts receivable, net of allowance for credit losses of $280,000 and $265,000 at March 31, 2025 and at December 31, 2024 | 0 |
| 0001437749-25-017106 | 2 | 12 | BS | 0 | H | Income Taxes Receivable | us-gaap/2025 | Tax receivables | 0 |
| 0001437749-25-017106 | 2 | 13 | BS | 0 | H | Other Receivables Net Current | us-gaap/2025 | Other receivables | 0 |
| 0001437749-25-017106 | 2 | 14 | BS | 0 | H | Prepaid Maintenance Current | 0001437749-25-017106 | Prepaid maintenance | 0 |
| 0001437749-25-017106 | 2 | 15 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2025 | Prepaid expenses and other current assets | 0 |
| 0001437749-25-017106 | 2 | 16 | BS | 0 | H | Assets Current | us-gaap/2025 | Total current assets | 0 |
| 0001437749-25-017106 | 2 | 17 | BS | 0 | H | Property Plant And Equipment Net Excluding Land | 0001437749-25-017106 | Property and equipment, net | 0 |
| 0001437749-25-017106 | 2 | 18 | BS | 0 | H | Land | us-gaap/2025 | Land | 0 |
| 0001437749-25-017106 | 2 | 19 | BS | 0 | H | Goodwill | us-gaap/2025 | Goodwill | 0 |
| 0001437749-25-017106 | 2 | 20 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2025 | Intangible asset | 0 |
| 0001437749-25-017106 | 2 | 21 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2025 | Right of use assets, net | 0 |
| 0001437749-25-017106 | 2 | 22 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2025 | Other assets | 0 |
| 0001437749-25-017106 | 2 | 23 | BS | 0 | H | Assets | us-gaap/2025 | Total assets | 0 |
| 0001437749-25-017106 | 2 | 25 | BS | 0 | H | Accounts Payable Current | us-gaap/2025 | Accounts payable | 0 |
| 0001437749-25-017106 | 2 | 26 | BS | 0 | H | Employee Related Liabilities Current | us-gaap/2025 | Employee compensation and benefits | 0 |
| 0001437749-25-017106 | 2 | 27 | BS | 0 | H | Other Accrued Liabilities Current | us-gaap/2025 | Other accrued liabilities | 0 |
| 0001437749-25-017106 | 2 | 28 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2025 | Related party liabilities | 0 |
| 0001437749-25-017106 | 2 | 29 | BS | 0 | H | Asset Retirement Obligation Related Party Current | 0001437749-25-017106 | Asset retirement obligations, related party (includes $250,000 and $250,000 non-related party at March 31, 2025 and December 31, 2024) | 0 |
| 0001437749-25-017106 | 2 | 30 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2025 | Current portion of lease liabilities | 0 |
| 0001437749-25-017106 | 2 | 31 | BS | 0 | H | Lines Of Credit Current | us-gaap/2025 | Line of credit | 0 |
| 0001437749-25-017106 | 2 | 32 | BS | 0 | H | Long Term Debt Current | us-gaap/2025 | Current portion of long-term debt, net | 0 |
| 0001437749-25-017106 | 2 | 33 | BS | 0 | H | Liabilities Current | us-gaap/2025 | Total current liabilities | 0 |
| 0001437749-25-017106 | 2 | 34 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2025 | Long-term lease liabilities, less current portion | 0 |
| 0001437749-25-017106 | 2 | 35 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2025 | Long-term debt, net, less current portion | 0 |
| 0001437749-25-017106 | 2 | 36 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2025 | Deferred income taxes | 0 |
| 0001437749-25-017106 | 2 | 37 | BS | 0 | H | Liabilities | us-gaap/2025 | Total liabilities | 0 |
| 0001437749-25-017106 | 2 | 38 | BS | 0 | H | Commitments And Contingencies | us-gaap/2025 | Commitments (see Note 9) | 0 |
| 0001437749-25-017106 | 2 | 40 | BS | 0 | H | Common Stock Value | us-gaap/2025 | Common stock, no par value (10,000,000 authorized shares; Issued and outstanding shares - 6,450,000 at March 31, 2025 and 6,420,000 at December 31, 2024) | 0 |
| 0001437749-25-017106 | 2 | 41 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2025 | Additional paid-in capital | 0 |
| 0001437749-25-017106 | 2 | 42 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2025 | Retained earnings | 0 |
| 0001437749-25-017106 | 2 | 43 | BS | 0 | H | Stockholders Equity | us-gaap/2025 | Total equity-American Shared Hospital Services | 0 |
| 0001437749-25-017106 | 2 | 44 | BS | 0 | H | Minority Interest | us-gaap/2025 | Non-controlling interests in subsidiaries | 0 |
| 0001437749-25-017106 | 2 | 45 | BS | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | Total shareholders' equity | 0 |
| 0001437749-25-017106 | 2 | 46 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2025 | Total liabilities and shareholders' equity | 0 |
| 0001437749-25-017106 | 3 | 5 | BS | 1 | H | Allowance For Doubtful Accounts Receivable Current | us-gaap/2025 | Allowance for doubtful accounts | 0 |
| 0001437749-25-017106 | 3 | 6 | BS | 1 | H | Asset Retirement Obligation Current | us-gaap/2025 | Asser retirement obligations, non-related party | 0 |
| 0001437749-25-017106 | 3 | 7 | BS | 1 | H | Common Stock No Par Value | us-gaap/2025 | Common stock, no par value (in dollars per share) | 0 |
| 0001437749-25-017106 | 3 | 8 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2025 | Common stock, shares authorized (in shares) | 0 |
| 0001437749-25-017106 | 3 | 9 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2025 | Common stock, shares issued (in shares) | 0 |
| 0001437749-25-017106 | 3 | 10 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2025 | Common stock, shares outstanding (in shares) | 0 |
| 0001437749-25-017106 | 4 | 10 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2025 | Revenues | 0 |
| 0001437749-25-017106 | 4 | 12 | IS | 0 | H | Direct Operating Maintenance Supplies Costs | us-gaap/2025 | Maintenance and supplies | 0 |
| 0001437749-25-017106 | 4 | 13 | IS | 0 | H | Cost Depreciation Amortization And Depletion | us-gaap/2025 | Depreciation and amortization | 0 |
| 0001437749-25-017106 | 4 | 14 | IS | 0 | H | Other Cost Of Operating Revenue | us-gaap/2025 | Other direct operating costs | 0 |
| 0001437749-25-017106 | 4 | 15 | IS | 0 | H | Other Cost Of Operating Revenue Related Party | 0001437749-25-017106 | Other direct operating costs, related party | 0 |
| 0001437749-25-017106 | 4 | 16 | IS | 0 | H | Cost Of Revenue | us-gaap/2025 | Cost of Revenue | 0 |
| 0001437749-25-017106 | 4 | 17 | IS | 0 | H | Gross Profit | us-gaap/2025 | Gross margin | 0 |
| 0001437749-25-017106 | 4 | 18 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2025 | Selling and administrative expense | 0 |
| 0001437749-25-017106 | 4 | 19 | IS | 0 | H | Interest Expense | us-gaap/2025 | Interest expense | 0 |
| 0001437749-25-017106 | 4 | 20 | IS | 0 | H | Operating Income Loss | us-gaap/2025 | Operating loss | 0 |
| 0001437749-25-017106 | 4 | 21 | IS | 0 | H | Interest And Other Income Loss | 0001437749-25-017106 | Interest and other income, net | 0 |
| 0001437749-25-017106 | 4 | 22 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2025 | (Loss) income before income taxes | 0 |
| 0001437749-25-017106 | 4 | 23 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2025 | Income tax benefit | 0 |
| 0001437749-25-017106 | 4 | 24 | IS | 0 | H | Profit Loss | us-gaap/2025 | Net (loss) income | 0 |
| 0001437749-25-017106 | 4 | 25 | IS | 0 | H | Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2025 | Plus: net loss attributable to non-controlling interests | 1 |
| 0001437749-25-017106 | 4 | 26 | IS | 0 | H | Net Income Loss | us-gaap/2025 | Net (loss) income attributable to American Shared Hospital Services | 0 |
| 0001437749-25-017106 | 4 | 28 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2025 | Basic (loss) earnings per share (in dollars per share) | 0 |
| 0001437749-25-017106 | 4 | 29 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2025 | Diluted (loss) earnings per share (in dollars per share) | 0 |
| 0001437749-25-017106 | 4 | 30 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2025 | Weighted average common shares for basic (loss) earnings per share (in shares) | 0 |
| 0001437749-25-017106 | 4 | 31 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2025 | Weighted average common shares for diluted (loss) earnings per share (in shares) | 0 |
| 0001437749-25-017106 | 5 | 13 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2025 | Balances (in shares) | 0 |
| 0001437749-25-017106 | 5 | 14 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | Balances | 0 |
| 0001437749-25-017106 | 5 | 15 | EQ | 0 | H | Stock Issued During Period Value Share Based Compensation | us-gaap/2025 | Stock-based compensation expense | 0 |
| 0001437749-25-017106 | 5 | 16 | EQ | 0 | H | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2025 | Vested restricted stock awards (in shares) | 0 |
| 0001437749-25-017106 | 5 | 17 | EQ | 0 | H | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2025 | Vested restricted stock awards | 0 |
| 0001437749-25-017106 | 5 | 18 | EQ | 0 | H | Noncontrolling Interest Increase From Subsidiary Equity Issuance | us-gaap/2025 | Capital contributions from non-controlling interests | 0 |
| 0001437749-25-017106 | 5 | 19 | EQ | 0 | H | Minority Interest Decrease From Distributions To Noncontrolling Interest Holders | us-gaap/2025 | Cash distributions to non-controlling interests | 1 |
| 0001437749-25-017106 | 5 | 20 | EQ | 0 | H | Profit Loss | us-gaap/2025 | Net (loss) income | 0 |
| 0001437749-25-017106 | 5 | 21 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2025 | Balances (in shares) | 0 |
| 0001437749-25-017106 | 5 | 22 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | Balances | 0 |
| 0001437749-25-017106 | 6 | 6 | CF | 0 | H | Profit Loss | us-gaap/2025 | Net (loss) income | 0 |
| 0001437749-25-017106 | 6 | 8 | CF | 0 | H | Depreciation And Amortization | us-gaap/2025 | Depreciation, amortization, and other | 0 |
| 0001437749-25-017106 | 6 | 9 | CF | 0 | H | Amortization Of Financing Costs | us-gaap/2025 | Accretion of debt issuance costs | 0 |
| 0001437749-25-017106 | 6 | 10 | CF | 0 | H | Noncash Lease Expense | 0001437749-25-017106 | Non cash lease expense | 0 |
| 0001437749-25-017106 | 6 | 11 | CF | 0 | H | Unfavorable Lease Position | 0001437749-25-017106 | Accretion of unfavorable lease position | 1 |
| 0001437749-25-017106 | 6 | 12 | CF | 0 | H | Deferred Income Tax Expense Benefit | us-gaap/2025 | Deferred income taxes | 0 |
| 0001437749-25-017106 | 6 | 13 | CF | 0 | H | Share Based Compensation | us-gaap/2025 | Stock-based compensation expense | 0 |
| 0001437749-25-017106 | 6 | 15 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2025 | Receivables | 1 |
| 0001437749-25-017106 | 6 | 16 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2025 | Prepaid expenses and other assets | 1 |
| 0001437749-25-017106 | 6 | 17 | CF | 0 | H | Increase Decrease In Due To Related Parties | us-gaap/2025 | Related party liabilities | 0 |
| 0001437749-25-017106 | 6 | 18 | CF | 0 | H | Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2025 | Accounts payable and accrued liabilities | 0 |
| 0001437749-25-017106 | 6 | 19 | CF | 0 | H | Increase Decrease In Accrued Income Taxes Payable | us-gaap/2025 | Income taxes payable | 0 |
| 0001437749-25-017106 | 6 | 20 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2025 | Lease liabilities | 0 |
| 0001437749-25-017106 | 6 | 21 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2025 | Net cash provided by (used in) operating activities | 0 |
| 0001437749-25-017106 | 6 | 23 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2025 | Payment for purchases of property and equipment | 1 |
| 0001437749-25-017106 | 6 | 24 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2025 | Net cash used in investing activities | 0 |
| 0001437749-25-017106 | 6 | 26 | CF | 0 | H | Repayments Of Long Term Debt | us-gaap/2025 | Principal payments on long-term debt | 1 |
| 0001437749-25-017106 | 6 | 27 | CF | 0 | H | Repayments Of Long Term Lines Of Credit | us-gaap/2025 | Payments on line of credit | 1 |
| 0001437749-25-017106 | 6 | 28 | CF | 0 | H | Proceeds From Lines Of Credit | us-gaap/2025 | Advances on line of credit | 0 |
| 0001437749-25-017106 | 6 | 29 | CF | 0 | H | Proceeds From Issuance Of Long Term Debt | us-gaap/2025 | Long-term debt financing | 0 |
| 0001437749-25-017106 | 6 | 30 | CF | 0 | H | Proceeds From Minority Shareholders | us-gaap/2025 | Capital contribution non-controlling interests | 0 |
| 0001437749-25-017106 | 6 | 31 | CF | 0 | H | Payments To Minority Shareholders | us-gaap/2025 | Distributions to non-controlling interests | 1 |
| 0001437749-25-017106 | 6 | 32 | CF | 0 | H | Payments Of Debt Issuance Costs | us-gaap/2025 | Debt issuance costs long-term debt | 1 |
| 0001437749-25-017106 | 6 | 33 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2025 | Net cash provided by financing activities | 0 |
| 0001437749-25-017106 | 6 | 34 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2025 | Net change in cash, cash equivalents, and restricted cash | 0 |
| 0001437749-25-017106 | 6 | 35 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2025 | Cash, cash equivalents, and restricted cash at beginning of period | 0 |
| 0001437749-25-017106 | 6 | 36 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2025 | Cash, cash equivalents, and restricted cash at end of period | 0 |
| 0001437749-25-017106 | 6 | 38 | CF | 0 | H | Interest Paid Net | us-gaap/2025 | Interest | 0 |
| 0001437749-25-017106 | 6 | 39 | CF | 0 | H | Income Taxes Paid Net | us-gaap/2025 | Income taxes | 0 |
| 0001437749-25-017106 | 6 | 41 | CF | 0 | H | Capital Expenditures Incurred But Not Yet Paid | us-gaap/2025 | Equipment included in accounts payable and accrued liabilities | 0 |
| 0001437749-25-017106 | 6 | 42 | CF | 0 | H | Right Of Use Asset Obtained In Exchange For Operating Lease Liability | us-gaap/2025 | Right of use assets and lease liabilities | 0 |
| 0001437749-25-017106 | 6 | 43 | CF | 0 | H | Increase To Right Of Use Assets And Lease Liabilities Due To Lease Modification | 0001437749-25-017106 | Increase to right of use assets and lease liabilities due to a lease modification | 0 |
| 0001437749-25-017106 | 6 | 45 | CF | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | Cash and cash equivalents | 0 |
| 0001437749-25-017106 | 6 | 46 | CF | 0 | H | Restricted Cash | us-gaap/2025 | Restricted cash | 0 |
| 0001437749-25-017106 | 6 | 47 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2025 | Cash, cash equivalents, and restricted cash at end of period | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |